Skip to content

Revelation Biosciences, Inc.

REVB· NasdaqCore metricsCIK 1810560

Pharmaceutical preparations552 peers

Last sale
Nov 12, 2026 · +3.55%
Market cap
$2.99M
683.44K shares
Filings
390
—
—
—
-$3.32M
Q3 2026N/M FY25 yoy
-$3.38M
Q3 2026N/M FY25 yoy
-$8.24M
Q3 2026derivedN/M FY24 yoy
-$5.92
Q3 2026N/M FY25 yoy
$9.12M
Q3 2026+64.6% FY25 yoy
$2.99M
—
—
0.4×
—
—

FY2025 figures · derived

Price

$4.38+10.67%+$0.42past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of record

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Net Interest Income

$68.06KQ3 2026
No annual history for this metric yet.
PeriodEndedValueKindSource trail

Capital returns

Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2021—$35.50M$35.50M—15.08M sh+65.8%—

Pharmaceutical preparations

Revelation Biosciences, Inc. is the 474th largest of the 553 covered companies the SEC files under this code, by market cap. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Revelation Biosciences, Inc. · CIK 1810560 · Engraved from SEC EDGAR